Monica M. Montano

Sources

Sources are listed once and connected to each accepted claim they support. Excerpts preserve the source language used in the review.

1. [1]

   Monica M. Montano | Pathology | School of Medicine | Case Western Reserve University

   8 source claims · Reviewed Sep 9, 2026

   Show supporting evidence

   Biographical context: I still do benchwork, tissue culture, and animal work, allowing me to participate in and closely monitor the development of research projects.

   Monica M. Montano, PhD Email [contact withheld] Phone [contact withheld] Fax Number [contact withheld] Office Location: Wood Building W307 Mailing Address 10900 Euclid Ave Cleveland, OH 44106-4965 Professor, Department of Pharmacology, School of Medicine Director, Heart, School of Medicine Member, Developmental Therapeutics Program, Case Comprehensive Cancer Center A major research focus in my laboratory is the identification of factors underlying the hormonal responsiveness of human cancers and to determine how to inhibit growth of hormone responsive cancers (i.e. breast and prostate cancers). My laboratory has now broadened their efforts to the identification of factors in breast and prostate cancer critical in the transition to hormone-independence, resistance to cancer therapeutics, and ability to metastasize. We were one of two laboratories to first identify Hexamethylene bisacetamide (HMBA) Induced Protein 1 (HEXIM1), the main focus of this grant. HEXIM1 was originally identified as Estrogen Down Regulated Gene 1 (EDG1), an Estrogen Receptor interacting and corepressor factor that is downregulated by estrogens. We later determined that HEXIM1 inhibits the growth of hormone responsive cancers, and required for inhibitory actions of antiestrogens and antiandrogens (agents that represent the mainstay in the treatment of hormone responsive breast and prostate cancers). We also looked outside the "box" of epithelial cells, and elucidated HEXIM1 functions in the context of the mammary microenvironment. Our findings suggest that HEXIM1 is a master inhibitor of tumor derived factors critical for the development of the metastatic niche. Thus, loss of HEXIM1 in early carcinomas may contribute to the progression to metastatic disease, but is therapeutically addressable. We are exploring the translational potential of HEXIM1 by developing methods for localized and prolonged delivery of HMBA through the use of polymers to upregulate HEXIM1 expression in breast and prostate cancers. We also identified a HMBA derivative, 4a1, that is more potent than its parent compound at upregulating HEXIM1 expression. More recently, we identified a potential new target for HMBA and its derivative that opened up a new lead optimization direction for a group of compounds we now refer to as “HEXIM1 Inducers” To achieve our research goals my laboratory uses a vast array of techniques. My laboratory has extensive experience in transcriptional regulation, genomic approaches, and the development and use of animal models to validate our mechanistic. I still do benchwork, tissue culture, and animal work, allowing me to participate in and closely monitor the development of research projects.

   Degree: PhD

   Monica M. Montano, PhD Email [contact withheld] Phone [contact withheld] Fax Number [contact withheld] Office Location: Wood Building W307 Mailing Address 10900 Euclid Ave Cleveland, OH 44106-4965 Professor, Department of Pharmacology, School of Medicine Director, Heart, School of Medicine Member, Developmental Therapeutics Program, Case Comprehensive Cancer Center A major research focus in my laboratory is the identification of factors underlying the hormonal responsiveness of human cancers and to determine how to inhibit growth of hormone responsive cancers (i.e. breast and prostate cancers). My laboratory has now broadened their efforts to the identification of factors in breast and prostate cancer critical in the transition to hormone-independence, resistance to cancer therapeutics, and ability to metastasize. We were one of two laboratories to first identify Hexamethylene bisacetamide (HMBA) Induced Protein 1 (HEXIM1), the main focus of this grant. HEXIM1 was originally identified as Estrogen Down Regulated Gene 1 (EDG1), an Estrogen Receptor interacting and corepressor factor that is downregulated by estrogens. We later determined that HEXIM1 inhibits the growth of hormone responsive cancers, and required for inhibitory actions of antiestrogens and antiandrogens (agents that represent the mainstay in the treatment of hormone responsive breast and prostate cancers). We also looked outside the "box" of epithelial cells, and elucidated HEXIM1 functions in the context of the mammary microenvironment. Our findings suggest that HEXIM1 is a master inhibitor of tumor derived factors critical for the development of the metastatic niche. Thus, loss of HEXIM1 in early carcinomas may contribute to the progression to metastatic disease, but is therapeutically addressable. We are exploring the translational potential of HEXIM1 by developing methods for localized and prolonged delivery of HMBA through the use of polymers to upregulate HEXIM1 expression in breast and prostate cancers. We also identified a HMBA derivative, 4a1, that is more potent than its parent compound at upregulating HEXIM1 expression. More recently, we identified a potential new target for HMBA and its derivative that opened up a new lead optimization direction for a group of compounds we now refer to as “HEXIM1 Inducers” To achieve our research goals my laboratory uses a vast array of techniques. My laboratory has extensive experience in transcriptional regulation, genomic approaches, and the development and use of animal models to validate our mechanistic. I still do benchwork, tissue culture, and animal work, allowing me to participate in and closely monitor the development of research projects.

   Identity: Monica M. Montano

   Monica M. Montano, PhD Email [contact withheld] Phone [contact withheld] Fax Number [contact withheld] Office Location: Wood Building W307 Mailing Address 10900 Euclid Ave Cleveland, OH 44106-4965 Professor, Department of Pharmacology, School of Medicine Director, Heart, School of Medicine Member, Developmental Therapeutics Program, Case Comprehensive Cancer Center A major research focus in my laboratory is the identification of factors underlying the hormonal responsiveness of human cancers and to determine how to inhibit growth of hormone responsive cancers (i.e. breast and prostate cancers). My laboratory has now broadened their efforts to the identification of factors in breast and prostate cancer critical in the transition to hormone-independence, resistance to cancer therapeutics, and ability to metastasize. We were one of two laboratories to first identify Hexamethylene bisacetamide (HMBA) Induced Protein 1 (HEXIM1), the main focus of this grant. HEXIM1 was originally identified as Estrogen Down Regulated Gene 1 (EDG1), an Estrogen Receptor interacting and corepressor factor that is downregulated by estrogens. We later determined that HEXIM1 inhibits the growth of hormone responsive cancers, and required for inhibitory actions of antiestrogens and antiandrogens (agents that represent the mainstay in the treatment of hormone responsive breast and prostate cancers). We also looked outside the "box" of epithelial cells, and elucidated HEXIM1 functions in the context of the mammary microenvironment. Our findings suggest that HEXIM1 is a master inhibitor of tumor derived factors critical for the development of the metastatic niche. Thus, loss of HEXIM1 in early carcinomas may contribute to the progression to metastatic disease, but is therapeutically addressable. We are exploring the translational potential of HEXIM1 by developing methods for localized and prolonged delivery of HMBA through the use of polymers to upregulate HEXIM1 expression in breast and prostate cancers. We also identified a HMBA derivative, 4a1, that is more potent than its parent compound at upregulating HEXIM1 expression. More recently, we identified a potential new target for HMBA and its derivative that opened up a new lead optimization direction for a group of compounds we now refer to as “HEXIM1 Inducers” To achieve our research goals my laboratory uses a vast array of techniques. My laboratory has extensive experience in transcriptional regulation, genomic approaches, and the development and use of animal models to validate our mechanistic. I still do benchwork, tissue culture, and animal work, allowing me to participate in and closely monitor the development of research projects.

   Professional role: Director, Heart, School of Medicine

   Monica M. Montano, PhD Email [contact withheld] Phone [contact withheld] Fax Number [contact withheld] Office Location: Wood Building W307 Mailing Address 10900 Euclid Ave Cleveland, OH 44106-4965 Professor, Department of Pharmacology, School of Medicine Director, Heart, School of Medicine Member, Developmental Therapeutics Program, Case Comprehensive Cancer Center A major research focus in my laboratory is the identification of factors underlying the hormonal responsiveness of human cancers and to determine how to inhibit growth of hormone responsive cancers (i.e. breast and prostate cancers). My laboratory has now broadened their efforts to the identification of factors in breast and prostate cancer critical in the transition to hormone-independence, resistance to cancer therapeutics, and ability to metastasize. We were one of two laboratories to first identify Hexamethylene bisacetamide (HMBA) Induced Protein 1 (HEXIM1), the main focus of this grant. HEXIM1 was originally identified as Estrogen Down Regulated Gene 1 (EDG1), an Estrogen Receptor interacting and corepressor factor that is downregulated by estrogens. We later determined that HEXIM1 inhibits the growth of hormone responsive cancers, and required for inhibitory actions of antiestrogens and antiandrogens (agents that represent the mainstay in the treatment of hormone responsive breast and prostate cancers). We also looked outside the "box" of epithelial cells, and elucidated HEXIM1 functions in the context of the mammary microenvironment. Our findings suggest that HEXIM1 is a master inhibitor of tumor derived factors critical for the development of the metastatic niche. Thus, loss of HEXIM1 in early carcinomas may contribute to the progression to metastatic disease, but is therapeutically addressable. We are exploring the translational potential of HEXIM1 by developing methods for localized and prolonged delivery of HMBA through the use of polymers to upregulate HEXIM1 expression in breast and prostate cancers. We also identified a HMBA derivative, 4a1, that is more potent than its parent compound at upregulating HEXIM1 expression. More recently, we identified a potential new target for HMBA and its derivative that opened up a new lead optimization direction for a group of compounds we now refer to as “HEXIM1 Inducers” To achieve our research goals my laboratory uses a vast array of techniques. My laboratory has extensive experience in transcriptional regulation, genomic approaches, and the development and use of animal models to validate our mechanistic. I still do benchwork, tissue culture, and animal work, allowing me to participate in and closely monitor the development of research projects.

   Professional role: Member, Developmental Therapeutics Program, Case Comprehensive Cancer Center

   Monica M. Montano, PhD Email [contact withheld] Phone [contact withheld] Fax Number [contact withheld] Office Location: Wood Building W307 Mailing Address 10900 Euclid Ave Cleveland, OH 44106-4965 Professor, Department of Pharmacology, School of Medicine Director, Heart, School of Medicine Member, Developmental Therapeutics Program, Case Comprehensive Cancer Center A major research focus in my laboratory is the identification of factors underlying the hormonal responsiveness of human cancers and to determine how to inhibit growth of hormone responsive cancers (i.e. breast and prostate cancers). My laboratory has now broadened their efforts to the identification of factors in breast and prostate cancer critical in the transition to hormone-independence, resistance to cancer therapeutics, and ability to metastasize. We were one of two laboratories to first identify Hexamethylene bisacetamide (HMBA) Induced Protein 1 (HEXIM1), the main focus of this grant. HEXIM1 was originally identified as Estrogen Down Regulated Gene 1 (EDG1), an Estrogen Receptor interacting and corepressor factor that is downregulated by estrogens. We later determined that HEXIM1 inhibits the growth of hormone responsive cancers, and required for inhibitory actions of antiestrogens and antiandrogens (agents that represent the mainstay in the treatment of hormone responsive breast and prostate cancers). We also looked outside the "box" of epithelial cells, and elucidated HEXIM1 functions in the context of the mammary microenvironment. Our findings suggest that HEXIM1 is a master inhibitor of tumor derived factors critical for the development of the metastatic niche. Thus, loss of HEXIM1 in early carcinomas may contribute to the progression to metastatic disease, but is therapeutically addressable. We are exploring the translational potential of HEXIM1 by developing methods for localized and prolonged delivery of HMBA through the use of polymers to upregulate HEXIM1 expression in breast and prostate cancers. We also identified a HMBA derivative, 4a1, that is more potent than its parent compound at upregulating HEXIM1 expression. More recently, we identified a potential new target for HMBA and its derivative that opened up a new lead optimization direction for a group of compounds we now refer to as “HEXIM1 Inducers” To achieve our research goals my laboratory uses a vast array of techniques. My laboratory has extensive experience in transcriptional regulation, genomic approaches, and the development and use of animal models to validate our mechanistic. I still do benchwork, tissue culture, and animal work, allowing me to participate in and closely monitor the development of research projects.

   Professional role: Professor, Department of Pharmacology, School of Medicine

   Monica M. Montano, PhD Email [contact withheld] Phone [contact withheld] Fax Number [contact withheld] Office Location: Wood Building W307 Mailing Address 10900 Euclid Ave Cleveland, OH 44106-4965 Professor, Department of Pharmacology, School of Medicine Director, Heart, School of Medicine Member, Developmental Therapeutics Program, Case Comprehensive Cancer Center A major research focus in my laboratory is the identification of factors underlying the hormonal responsiveness of human cancers and to determine how to inhibit growth of hormone responsive cancers (i.e. breast and prostate cancers). My laboratory has now broadened their efforts to the identification of factors in breast and prostate cancer critical in the transition to hormone-independence, resistance to cancer therapeutics, and ability to metastasize. We were one of two laboratories to first identify Hexamethylene bisacetamide (HMBA) Induced Protein 1 (HEXIM1), the main focus of this grant. HEXIM1 was originally identified as Estrogen Down Regulated Gene 1 (EDG1), an Estrogen Receptor interacting and corepressor factor that is downregulated by estrogens. We later determined that HEXIM1 inhibits the growth of hormone responsive cancers, and required for inhibitory actions of antiestrogens and antiandrogens (agents that represent the mainstay in the treatment of hormone responsive breast and prostate cancers). We also looked outside the "box" of epithelial cells, and elucidated HEXIM1 functions in the context of the mammary microenvironment. Our findings suggest that HEXIM1 is a master inhibitor of tumor derived factors critical for the development of the metastatic niche. Thus, loss of HEXIM1 in early carcinomas may contribute to the progression to metastatic disease, but is therapeutically addressable. We are exploring the translational potential of HEXIM1 by developing methods for localized and prolonged delivery of HMBA through the use of polymers to upregulate HEXIM1 expression in breast and prostate cancers. We also identified a HMBA derivative, 4a1, that is more potent than its parent compound at upregulating HEXIM1 expression. More recently, we identified a potential new target for HMBA and its derivative that opened up a new lead optimization direction for a group of compounds we now refer to as “HEXIM1 Inducers” To achieve our research goals my laboratory uses a vast array of techniques. My laboratory has extensive experience in transcriptional regulation, genomic approaches, and the development and use of animal models to validate our mechanistic. I still do benchwork, tissue culture, and animal work, allowing me to participate in and closely monitor the development of research projects.

   Research interests: the identification of factors underlying the hormonal responsiveness of human cancers and to determine how to inhibit growth of hormone responsive cancers (i.e. breast and prostate cancers)

   Monica M. Montano, PhD Email [contact withheld] Phone [contact withheld] Fax Number [contact withheld] Office Location: Wood Building W307 Mailing Address 10900 Euclid Ave Cleveland, OH 44106-4965 Professor, Department of Pharmacology, School of Medicine Director, Heart, School of Medicine Member, Developmental Therapeutics Program, Case Comprehensive Cancer Center A major research focus in my laboratory is the identification of factors underlying the hormonal responsiveness of human cancers and to determine how to inhibit growth of hormone responsive cancers (i.e. breast and prostate cancers). My laboratory has now broadened their efforts to the identification of factors in breast and prostate cancer critical in the transition to hormone-independence, resistance to cancer therapeutics, and ability to metastasize. We were one of two laboratories to first identify Hexamethylene bisacetamide (HMBA) Induced Protein 1 (HEXIM1), the main focus of this grant. HEXIM1 was originally identified as Estrogen Down Regulated Gene 1 (EDG1), an Estrogen Receptor interacting and corepressor factor that is downregulated by estrogens. We later determined that HEXIM1 inhibits the growth of hormone responsive cancers, and required for inhibitory actions of antiestrogens and antiandrogens (agents that represent the mainstay in the treatment of hormone responsive breast and prostate cancers). We also looked outside the "box" of epithelial cells, and elucidated HEXIM1 functions in the context of the mammary microenvironment. Our findings suggest that HEXIM1 is a master inhibitor of tumor derived factors critical for the development of the metastatic niche. Thus, loss of HEXIM1 in early carcinomas may contribute to the progression to metastatic disease, but is therapeutically addressable. We are exploring the translational potential of HEXIM1 by developing methods for localized and prolonged delivery of HMBA through the use of polymers to upregulate HEXIM1 expression in breast and prostate cancers. We also identified a HMBA derivative, 4a1, that is more potent than its parent compound at upregulating HEXIM1 expression. More recently, we identified a potential new target for HMBA and its derivative that opened up a new lead optimization direction for a group of compounds we now refer to as “HEXIM1 Inducers” To achieve our research goals my laboratory uses a vast array of techniques. My laboratory has extensive experience in transcriptional regulation, genomic approaches, and the development and use of animal models to validate our mechanistic. I still do benchwork, tissue culture, and animal work, allowing me to participate in and closely monitor the development of research projects.

   Research interests: transcriptional regulation, genomic approaches, and the development and use of animal models

   Monica M. Montano, PhD Email [contact withheld] Phone [contact withheld] Fax Number [contact withheld] Office Location: Wood Building W307 Mailing Address 10900 Euclid Ave Cleveland, OH 44106-4965 Professor, Department of Pharmacology, School of Medicine Director, Heart, School of Medicine Member, Developmental Therapeutics Program, Case Comprehensive Cancer Center A major research focus in my laboratory is the identification of factors underlying the hormonal responsiveness of human cancers and to determine how to inhibit growth of hormone responsive cancers (i.e. breast and prostate cancers). My laboratory has now broadened their efforts to the identification of factors in breast and prostate cancer critical in the transition to hormone-independence, resistance to cancer therapeutics, and ability to metastasize. We were one of two laboratories to first identify Hexamethylene bisacetamide (HMBA) Induced Protein 1 (HEXIM1), the main focus of this grant. HEXIM1 was originally identified as Estrogen Down Regulated Gene 1 (EDG1), an Estrogen Receptor interacting and corepressor factor that is downregulated by estrogens. We later determined that HEXIM1 inhibits the growth of hormone responsive cancers, and required for inhibitory actions of antiestrogens and antiandrogens (agents that represent the mainstay in the treatment of hormone responsive breast and prostate cancers). We also looked outside the "box" of epithelial cells, and elucidated HEXIM1 functions in the context of the mammary microenvironment. Our findings suggest that HEXIM1 is a master inhibitor of tumor derived factors critical for the development of the metastatic niche. Thus, loss of HEXIM1 in early carcinomas may contribute to the progression to metastatic disease, but is therapeutically addressable. We are exploring the translational potential of HEXIM1 by developing methods for localized and prolonged delivery of HMBA through the use of polymers to upregulate HEXIM1 expression in breast and prostate cancers. We also identified a HMBA derivative, 4a1, that is more potent than its parent compound at upregulating HEXIM1 expression. More recently, we identified a potential new target for HMBA and its derivative that opened up a new lead optimization direction for a group of compounds we now refer to as “HEXIM1 Inducers” To achieve our research goals my laboratory uses a vast array of techniques. My laboratory has extensive experience in transcriptional regulation, genomic approaches, and the development and use of animal models to validate our mechanistic. I still do benchwork, tissue culture, and animal work, allowing me to participate in and closely monitor the development of research projects.